全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 53902-12-8 |
|---|---|---|---|
| 分子式 | C18H17NO5 | 纯度 | 99% |
| 分子量 | 327.33 | 货号 | abs47028131 |
| 规格 | 10mg | 供货周期 | 现货 |
| 主要用途 | used for the treatment of allergic diso | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Tranilast 53902-12-8
| 产品描述 | |
| 描述 | Tranilast is an antiallergic drug by inhibiting lipid mediator and cytokine release from inflammatory cells, used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
| 纯度 | 99% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 曲尼si特；MK 341；SB 252218 |
| 外观 | 淡黄色或淡黄绿色结晶性粉末 |
| 可溶性/溶解性 | DMSO : 32.7 mg/mL (100 mM) |
| 生物活性 | |
| 靶点 | Angiotensin Receptor |
| In vitro(体外研究) | Tranilast is an anti-allergic drug inhibiting the release of substances such as histamine and prostaglandins from mast cells, which suppresses collagen synthesis of fibroblasts derived from keloid tissues. Tranilast (3-300 mM) suppresses the collagen synthesis of fibroblasts from keloid and hypertrophic scar tissue but not healthy skin fibroblasts. Tranilast (30-300 mM) inhibits the release of transforming growth factor (TGF)-beta 1 from keloid fibroblasts, which enhances the collagen synthesis of keloid fibroblasts. Tranilast improves keloids and hypertrophic scars which originate from the abnormal proliferation and excessive collagen accumulation of fibroblasts. Tranilast inhibits the release of TGF-beta 1, IL-1 beta and PGE2 from the human monocytes-macrophages. Tranilast inhibits the proliferation stimulated with fetal bovine serum (FBS), TGF-beta 1 and platelet-derived growth factor-BB (PDGF-BB) as well as PDGF-BB-induced migration. Tranilast exhibits inhibitory effects on spontaneous collagen synthesis and TGF-beta 1-induced collagen and glycosaminoglycan synthesis. |
| In vivo(体内研究) | Tranilast results in a 58% reduction in TGF-beta1-induced 3-hydroxyproline incorporation in the diabetic heart of rats. Tranilast attenuates cardiac fibrosis by 37% in association with reduction in phospho-Smad2 in the diabetic heart of rats. Tranilast treatment completely prevents the increase in chymaselike activity, reduces the chymase mRNA levels by 43%, and decreases the carotid intima/media ratio by 63% in the carotid artery of dogs. |
| 参考文献 | |
| 参考文献 |
| 研究领域 | |
| 研究领域 | CancerCancer MetabolismCellular metabolic process CancerCancer MetabolismMetabolic signaling pathwayMetabolism of lipids and lipoproteins CardiovascularBloodBlood Pressure regulation CardiovascularBloodSerum Proteins CardiovascularVasculatureVasoconstrictionOther MetabolismPathways and ProcessesMetabolic signaling pathwaysLipid and lipoprotein metabolismLipid metabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：